Close
Blog & Resources Camargo Blog March 10th, 2010

FDA’s DAARP is now DAAP, DPAP is now DPARP

Effective March 15th, the FDA’s Division of Anesthesia, Analgesia, and Rheumatology Products is being reorganized. This reorganization is part of some other reassignments announced yesterday (3/09/2010) by the FDA.

The “R” part – Rheumatology, will move to the Division of Pulmonary and Allergy Products, which will be renamed the Division of Pulmonary, Allergy, and Rheumatology Products. The reviewers will move as will the applications under review. The FDA has provided a list of the IND’s and NDA’s that are affected for this DAARP to DPARP move.

The FDA announced the moves as needed to balance workload. Camargo’s experience with DAARP – we had 13 pre-IND meetings with them last year alone, indicated they did well meeting their PDUFA dates while under extreme pressure. One of the major initiatives at FDA, REMS is focused at many of the products reviewed by this Division. The burden of finding ways to deal with the abuse of opioids and the numerous sponsor views has also added to its workload. Presumably, the reassignment of rheumatology products will help.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights